Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
 
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Poster Sessions - Poster Session 5

Poster Session 5 
   
  Tumor Cell and Molecular Biology: Immunology and Preclinical Immunotherapy
P5-01-01 Lymphoid tissue inducer cells: Identification of a novel immune cell within the breast tumour microenvironment and its role in promoting tumour cell invasion
Irshad S, Lawler K, Evans R, Flores-Borja F, Monypenny J, Grigoriadis A, Fruhwith G, Poland S, Barber P, Vojnovic B, Ellis P, Tutt A, Ng T. Breakthrough Breast Cancer Research Unit, London, England, United Kingdom; Randall Division & Division of Cancer Studies, London, England, United Kingdom; Gray Institute for Radiation Oncology & Biology, Oxford, United Kingdom.
P5-01-02 Characterization of follicular helper CD4 T cells and B cells resident in peritumoral tertiary lymphocyte structures as specific markers for an immunological grade in breast cancer
Willard-Gallo K, Garaud S, Buisseret L, Gu-Trantien C, Migliori E, Lodewyckx J-N, Naveaux C, de Wind A, Duquenne S, Larsimont D, Sotiriou C, Piccart M. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
P5-01-03 Withdrawn
P5-01-04 Activation of toll-like receptor 7 (TLR7) confers protection in human breast cancer
Obeid EI, Khramstova G, Zhang B, Fu Y-X, Mueller J, Nanda R, Olopade OI. University of Chicago, Chicago, IL.
P5-01-05 Personalized peptide vaccines in combination with conventional chemo- or endocrine therapy for metastatic breast cancer: A single-arm phase II study
Toh U, Iwakuma N, Mishima M, Takenaka M, Takahashi R, Koura K, Fujii T, Nakagawa S, Ogo E, Tanaka M, Sasada T, Itoh K, Shirouzu K. Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan.
P5-01-06 Remodeling the tumor immune microenvironment via intratumoral administration of immunomodulatory agents
Campbell MJ, Senman B, Esserman LJ. University of California, San Francisco, CA.
P5-01-07 Select neutrophils inhibit breast cancer metastases in patients via chemokine-mediated mechanisms
Comen EA, Granot Z, Blum B, Coker C, Shah R, Seshan V, Norton L, Benezra R. Memorial Sloan-Kettering Cancer Center, New York, NY; The Hebrew University of Jerusalem, Jerusalem, Israel.
P5-01-08 Changes induced by neoadjuvant chemotherapy (NCT) in breast cancer tumor infiltrating lymphocytes (TIL) subpopulations are associated with chemo-sensitivity and prognosis
García-Martínez E, Luengo-Gil G, Chaves A, Gonzalez-Billalabeitia E, García García T, Vicente Conesa MA, García Garre E, de la Morena P, Vicente V, Ayala de la Peña F. Hospital Morales Meseguer, Murcia, Spain.
P5-01-09 Early tumor antigens discovered in TgMMTV-neu mice may provide targets for early breast cancer diagnosis and prevention
Stanton SE, Mao J, Ladd J, Rastetter L, Gadd E, Hanash S, Disis ML. University of Washington, Seattle, WA; MD Anderson Cancer Center, Houston, TX.
P5-01-10 Adiponectin receptor signaling in dendritic cells inhibit anti-tumor responses in an animal model and breast cancer patients
Tan P, Xue S-A. Oxford University, Oxford, Oxon, United Kingdom; University College London, London, United Kingdom.
P5-01-11 A new anti-HER2 peptide "CH401MAP" can stimulate the immunity of breast cancer patients
Tsuda B, Kametani Y, Ohgiya R, Oshitanai R, Terao M, Terada M, Morioka T, Niikura N, Okamura T, Saito Y, Suzuki Y, Tokuda Y. Tokai University School of Medicine.
P5-01-12 Prognostic implications of tumor-infiltrating lymphocytes (TIL) in association with PD-L1 expression, and serum cytokine levels in early breast cancer
Park IH, Kong S-Y, Ro JY, Kwon Y, Kang JH, Mo HJ, Jung S-Y, Lee S, Lee KS, Kang H-S, Lee E, Ro J. Center for Breast Cancer, National Cancer Center; Breast & Endocrine Cancer Branch of Research Institute, National Cancer Center; National Cancer Center; The Methodist Hospital, Cornell University, Houston, TX.
P5-01-13 Poly(I:C), an innate adjuvant receptor ligand, can induce the antitumor effects on human breast cancer cells
Inao T, Harashima N, Yamamoto Y, Harada M, Iwase H. Kumamoto Univ. Hospital, Kumamoto, Japan; Shimane Univ. Facul. Med, Izumo, Shimane, Japan.
P5-01-14 Globo H ceramide is an ideal target of cancer immunotherapy: Its dual role as a cancer associated antigen, and as an immune checkpoint
Yu AL, Tsai Y-C, Huang Ji-R, Cheng J-Y, Lin J-J, Hung J-T, Wu Y-Y, Yeh K-T. Center of Stem Cell & Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan; University of California, San Diego, CA; Taipei City Hospital, Taipei; Changhua Christian Hospital, Changhua, Taiwan.
   
  Tumor Cell and Molecular Biology: Gene Therapy
P5-02-01 Regulated intratumoral expression of IL-12 in combination with cytotoxic agents as a strategy for the treatment of metastatic breast cancer
Nemunaitis J, McArthur H, Hudis C, Reed T, Broder S, Lebel F, Barrett J, Lewis J, Norton L. Mary Crowley Cancer Research Center, Dallas, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Intrexon Corporation, Germantown, MD; Ziopharm Oncology, Boston, MA.
P5-02-02 Specific gene delivery to Her-2+ breast cancer cells using immunoliposomes
Kullberg M, McCarthy R, Anchordoquy TJ. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO.
   
  Tumor Cell and Molecular Biology: Stem/Progenitor Cells
P5-03-01 Focal adhesion kinase inhibition abrogates ductal carcinoma in situ cancer stem cell activity and self-renewal capacity via down regulation of WNT3a and potentiates effects of radiation
Farnie G, Williams KE, Bundred NJ. University Hospital of South Manchester, Manchester, United Kingdom; Cancer Stem Cell Research, University of Manchester, Institute of Cancer Sciences, Manchester, United Kingdom.
P5-03-02 Expression of RANK and RANK ligand (RANKL) in breast carcinoma and distinct breast epithelial cells from BRCA1 mutation carriers
Lindeman GJ, Visvader JE, Vaillant F, Mann GB, Soriano R, Branstetter D, Dougall WC. The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; The Royal Melbourne Hospital, Parkville, VIC, Australia; The Royal Women's Hospital, Parkville, VIC, Australia; Amgen Inc., Seattle, WA; Therapeutic Innovation Unit, Amgen Inc., Seattle, WA.
P5-03-03 Effect of rapamycin on the function and transformation of aged murine mammary stem cells
Dong Q, Gao H, Wang D, Bandyopadhyay A, Wu A, Huang C, Sun L-Z. University of Texas Health Science Center at San Antonio, San Antonio, TX; Wenzhou Medical College, Wenzhou, Zhejiang, China.
P5-03-04 The meaning and significance of p63+/K5/14+ somatic stem cells of the normal breast salivary gland epithelium
Boecker W, Stenman G, Loening T, Andersson MK, Berg T, Buchwalow I. Institute for Hematopathology, Hamburg, Germany; Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden; Albertinen Pathology, Hamburg, Germany.
P5-03-05 Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules
Olsson H, Isfoss BL, Holmqvist B, Jernström H, Alm P. Clinical Sciences Lund, Lund University, Lund, Sweden.
P5-03-06 The relationship and clinical prognosis between ALDH1 expression in primary tumors and axillary lymph node metastases in invasive breast cancers
Dong Y, Shi A, Bi L, Xu N, Fan Z, Yang H, Li Y, Guan X. First Hospital of Jilin University, Changchun, Jilin, China; Lester – Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.
P5-03-07 CD24 epigenetic regulation in breast cancer tissues and tumor initiating cells: Promoter specific analysis using next generation sequencing
Park JH, Cui H, Vithayathil SA, Sung P-L, Zhang V, Wong L-JC, Kaipparettu BA. Baylor College of Medicine, Houston, TX.
P5-03-08 Mifepristone suppresses triple-negative breast cancer cell growth and cancer stem cell maintenance via down-regulating KLF5 expression
Liu R, Chen C. Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China.
P5-03-09 Phenotypic modulation of mammary stem cells by CAPE (caffeic acid phenethyl ester)
Omene C, Martinez H, Dave H, Vijayakumar S, Shah N, Li XL, Iizuka D, Barcellos-Hoff MH. NYU Langone Medical Center, New York, NY; Research Institute for Radiation Biology and Medicine Hiroshima University, Minami-ku, Hiroshima, Japan.
P5-03-10 Synergistic anti-proliferative effect of metformin and cisplatin in triple-negative breast cancer cell lines is inversely correlated with the number of CD44+CD24- stem cell resistant to metformin
Wysocki PJ, Gleboka A, Korski K, Suchorska W. Greater Poland Cancer Center, University of Medical Sciences, Poznan, Poland; Greater Poland Cancer Center, Poznan, Poland.
P5-03-11 Manassantin B significantly inhibits proliferation and stemness of triple-negative breast cancer (TNBC) cells
Gu J-W, Makey KL, Nagle DG, Zhou Y-D, Miele L. University of Mississippi Cancer Institute, Jackson, MS; University of Mississippi, University, MS.
P5-03-12 Prognostic role of stem cell markers in triple-negative breast cancer (TNBC)
Song J, Apple S, Goodglick L, Mah VH, Kim SR, Alavi MT, Chia D, Deng X, Chang HR. Gonda/UCLA Breast Cancer Research Laboratory, Los Angeles, CA; Revlon/UCLA Breast Center, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Kyung Hee University, Seoul, Republic of Korea.
P5-03-13 ASPM as a link between mammary tissue architectures, Wnt signaling pathways, breast cancer stemness and aggressiveness
Tsai KK-C. National Health Research Institutes, Tainan City, Taiwan.
P5-03-14 Low dose ionising radiation effects in normal breast progenitor sub-populations
Kavanagh JN, Kissenpfennig A, Irwin GW, Prise KM. Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom; Centre for Infection and Immunity, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
P5-03-15 Epithelial-to-mesenchymal transition; what is the impact on breast cancer stem cells and drug resistance
Mallini P, Lennard T, Kirby J, Meeson A. Newcastle University, Newcastle upon Tyne, United Kingdom.
   
  Tumor Cell and Molecular Biology: Progression, Invasion, and Metastasis
P5-04-01 Withdrawn
P5-04-02 Biopsy of metastases impacts treatment choice and patient outcome in breast cancer – Final results of the WSG/DETECT PRIMET study
Wuerstlein R, Kates R, Heitz F, Gluz O, Ortmann M, Freudenberger M, du Bois A, Bensmann E, Pelz E, Mallmann P, Fehm T, Nitz U, Liedtke C, Harbeck N. University Hospital Munich, Breast Center, CCC of LMU, Muenchen, Germany; WSG, Moenchengladbach, Germany; Klinikum Essen Mitte, Essen, Germany; University Hospital Cologne, Koeln, Germany; Ev. Bethesda-Krankenhaus, Moenchengladbach, Germany; University Hospital Duesseldorf, DETECT, Duesseldorf, Germany; University Hospital Luebeck, Luebeck, Germany.
P5-04-03 Bone morphogenic protein-4: A novel metastasis suppressor gene in breast cancer
Eckhardt BL, Cao Y, Loi S, Redfern A, Ueno NT, Parker BS, Anderson RL. The University of Texas at MD Anderson Cancer Center, Houston, TX; Trescowthick Research Laboratories, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; The University of Western Australia, Royal Perth Hospital Unit, Perth, WA, Australia; La Trobe Institute for Molecular Science, Melbourne, VIC, Australia.
P5-04-04 CCR5 antagonists block basal breast cancer and prostate cancer metastasis in vivo
Pestell RG, Jiao X, Velasco M, Sicoli D, Ju X, Pestll TG, Ertel A, Ando S. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Faculty of Pharmacy, Nutrition, and Health Science, University of Calabria, Arcavacata di Rende, CS, Italy.
P5-04-05 Preclinical modeling of luminal breast cancer: Recapitulating progression to lethal and tamoxifen-resistant lung metastases in novel patient-derived xenotransplant models in prolactin-humanized mice
Rui H, Zhang J, Yanac AF, Utama FE, Girondo MA, Peck AR, Rosenberg AL, Yang N. Thomas Jefferson University, Philadelphia, PA.
P5-04-06 Loss of the E3 ubiquitin ligase HACE1 plays a critical role in transformation of mammary cells and clinical progression of human breast cancer via accumulation of active Rac1
Goka ET, Lippman ME. University of Miami Miller School of Medicine, Miami, FL. Erik Goka is a recipient of an AACR Scholar-In-Training Award
P5-04-07 Withdrawn
P5-04-08 Modeling breast cancer dormancy
Wheeler SE, Taylor DP, Clark AM, Borenstein JT, Ebrahimkhani MR, Inman W, Nguyen T, Pillai VC, Prantil-Baun R, Ulrich TA, Venkataramanan R, Lauffenburger DA, Griffith L, Stolz DB, Wells A. University of Pittsburgh, Pittsburgh, PA; The Charles Stark Draper Laboratory, Inc, Cambridge, MA; Massachusetts Institute of Technology, Cambridge, MA. Sarah E. Wheeler is a recipient of an AACR Scholar-In-Training Award
P5-04-09 Redefining the breast tumor margin through genomics of the tumor-stromal interaction
Dhage S, Wang J, Zavadil J, Berman R, Axelrod D, Roses D, Schneider R. NYU School of Medicine, NY, NY; International Agency for Research on Cancer, Lyon, France.
P5-04-10 Chemokine receptor CXCR7 regulates macrophage thereby enhancing breast cancer growth and metastasis
Wani NA, Nasser MW, Ahirwar DK, Zhao H, Shilo K, Ganju RK. The Ohio State University, Columbus, OH.
P5-04-11 CDK11p58 inhibits estrogen receptor a positive breast cancer invasion via integrinβ3 through repressing ERa signaling
Chi Y, Wang L, Wang L, Wei P, Wu J. Breast Cancer Institute, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center.
P5-04-12 SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis
Ozturk S, Lambert A, Thiagalingam S. Boston University School of Medicine, Boston, MA.
P5-04-13 Antibody-based therapy targeting integrin α5 is an effective strategy to treat experimental breast cancer bone metastasis
Pantano F, Croset M, Driouch K, Santini D, Tonini G, Clézardin P. University Campus Bio-Medico, Rome, Italy; INSERM, Research Unit U1033, University of Lyon-1, Faculty of Medicine Laennec, F-69372, Lyon, France; Institut Curie, Paris, France.
P5-04-14 Loss of interferon regulatory factor 5 expression in breast cancer alters the tumor microenvironment to promote metastasis
Pimenta EM, Barnes BJ. Rutgers-NJMS Cancer Center, Newark, NJ.
P5-04-15 Investigating the role of the AMPK signaling cascade in breast cancer tumor dormancy
Sullivan KL, Phoenix KN, Fox MM, Kopsiaftis S, Claffey KP. University of Connecticut Health Center, Farmington, CT; Wingate University, Wingate, NC.
P5-04-16 Extracellular matrix 1 (ECM1) knockdown alters cellular characteristics, CD44 expression and other metastasis associated genes in breast cancer cells
Gomez-Contreras PC, Domann FE, Weigel RJ, Lal G. University of Iowa, Iowa City, IA.
P5-04-17 Rhapontigenin blocks cell migration and invasion by reducing Rac1 signaling in MDA-MB-231 breast cancer cells
Lee E-O, Kim J-S, Cho SM, Lee H-J, Kim S-H. Cancer Preventive Material Development Research Center, College of Oriental Medicine, Kyung Hee University, Seoul, Korea.
P5-04-18 Identification of a novel combination therapy that prevents the metastatic outgrowth and reduces the viability of dormant breast cancer cells: implications for clinical translation
El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE. Laboratory of Cancer Biology and Genetics, National Cancer Institute; Pediatric Oncology Branch, National Cancer Institute; Cellular and Molecular Pathology Branch, National Toxicology Program, National Institute of Environmental Health Sciences.
   
  Tumor Cell and Molecular Biology: Hormonal Factors and Receptors
P5-05-01 Endoxifen, a novel breast cancer therapy, elicits unique beneficial effects on bone relative to that of other selective estrogen receptor modulators
Hawse JR, Gingery A, Subramaniam M, Pitel KS, Lindenmaier LB, Iwaniec UT, Turner RT, Spelsberg TC, Ingle JN, Goetz MP. Mayo Clinic, Rochester, MN; Oregon State University, Corvallis, OR.
P5-05-02 Expression of androgen receptor and FOXA1 in non metastatic poor prognosis HER2- negative breast cancer: Ancillary study from UNICANCER-PACS08 multicenter trial
Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roché H, Lacroix-Triki M, Lemonnier J. Centre Georges-François Leclerc, Dijon, France; Centre Hospitalo-Universitaire, Besançon, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Unicancer, Paris, France.
P5-05-03 Progesterone receptor antagonists as inhibitors of breast cancer stem cell activity
Alferez D, Clarke RB, Cresta C, Mnene S, Howell SJ. Institute of Cancer Studies, University of Manchester, Manchester, United Kingdom; Oncology iMed, AstraZeneca, Macclesfield, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom.
P5-05-04 Relationship between plasma estradiol levels and estrogen-regulated gene expressions in premenopausal estrogen receptor-positive breast cancers
Toyama T, Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Takahashi S, Yamashita H. Immunology & Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
P5-05-05 Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy
van Verschuer VMT, Heemskerk-Gerritsen BAM, van Deurzen CHM, Obdeijn IM, Tilanus-Linthorst MMA, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C. Erasmus MC Cancer Institute, Rotterdam, Netherlands; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
P5-05-06 Menopausal status: An important consideration in determining the biology and prognosis of estrogen receptor-positive and progesterone receptor-negative breast cancer
Fujisue M, Nishimura R, Nakano M, Tashima R, Nishiyama Y, Osako T, Toyozumi Y, Arima N. Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan.
P5-05-07 Promestriene effects on estrogen-sensitive breast cancer cell proliferation in vitro
Almodovar AJO, Litherland SA, Courtneidge S, Decker DA. Florida Hospital Cancer Institute, Orlando, FL; Sanford-Burnham Medical Research Institute, La Jolla, CA.
P5-05-08 Obesity suppresses estrogen receptor beta expression in breast cancer cells via a HER2-mediated pathway
Wiese MA, Bowers LW, Tekmal RR, Brenner AJ, Hursting SD, deGraffenried LA. University of Texas at Austin; University of Texas Health Science Center at San Antonio.
P5-05-09 Extract ERr731® does not mimic estrogen stimulated growth of MNU-induced breast cancer in ovariectomized Sprague-Dawley rats
Vollmer G, Möller FJ, Zierau O, Macejova D. Technische Universität Dresden, Dresden, Germany; Institute of Experimental Endocrinology, Bratislava, Slovakia (Slovak Republic).
P5-05-10 Estrogenic pathways exist in TNBC and correlate with androgen receptor status
McNamara KM, Yoda T, Nurani AM, Miki Y, Suzuki T, Nemoto N, Miyashita M, Tamaki K, Ishida T, Ohuchi N, Sasano H. Tohoku University School of Graduate Medicine, Japan; Nahanishi Clinic, Japan.
   
  Tumor Cell and Molecular Biology: Growth Factors
P5-06-01 The PI3K inhibitor GDC-0941 combines with trastuzumab for superior anti-tumor efficacy in HER2+ breast cancer models
De P, Sun Y, Carlson J, Friedman L, Dey N, Leyland-Jones B. Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA.
P5-06-02 Activation of PI3K/Akt/mTOR pathway but not of MAPK pathway may be associated with luminal B subtype irrespective of menopausal status
Ayako Y, Michiko I, Keiko M, Yukie E, Sigetoshi I, Yoshimasa M, Arisa N, Yuichi T, Mitunori S, Toyomasa K, Yasuo M. Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Tokushima Breast Care Clinic, Tokushima, Japan; University Tokushima, Tokushima, Japan.
P5-06-03 Withdrawn
P5-06-04 Withdrawn
   
  Tumor Cell and Molecular Biology: Oncogenes and Tumor Suppressor Genes
P5-07-01 Withdrawn
P5-07-02 Mutant GATA3 causes precocious lobuloalveolar development in the mouse mammary gland and is associated with more aggressive human breast cancer
Kenny PA, Chandiramani N, Peterson EA. Albert Einstein College of Medicine, Bronx, NY.
P5-07-03 The nuclear coactivator amplified in breast cancer 1 maintains tumor initiating cells during development of ductal carcinoma in situ
Ory V, Tassi E, Cavalli LR, Sharif GM, Saenz F, Baker T, Schmidt MO, Mueller SC, Furth PA, Wellstein A, Riegel AT. Lombardi Cancer Center, Georgetown University, Washington, DC.
P5-07-04 Withdrawn
P5-07-05 Oncogene PELP1 regulates alternative splicing in breast cancer through PRMT6
Mann M, Vadlamudi RK. University of Texas Health Science Center at San Antonio, San Antonio, TX.
P5-07-06 Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis
Pestell RG, Casimiro MC, Crosariol M, Loro E, Dampier W, Di Sante G, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, Fortina P, Tozeren A, Knudsen ES, Arnold A. Thomas Jefferson University, Philadelphia, PA; Drexel University, Philadelphia, PA; University of Conneticut, Farmington, CT; University of Manchester, Manchester, England, United Kingdom; Southwestern Medical Center, Dallas, TX.
P5-07-07 Prognostic value of mutant TP53 in basal breast cancer
Park JY, Choi JE, Lee JH, Son GT, Kang SH, Bae YK, Lee SJ. Yeungnam University College of Medicine, Daegu, Republic of Korea.
P5-07-08 Restoration of APC decreases tumorigenic potential in breast cancer cells
Cole JM, Prosperi JR. Indiana University School of Medicine, South Bend, IN; Harper Cancer Research Institute, South Bend, IN.
P5-07-09 An aberrant spliced transcript of focal adhesion kinase expressed in human breast cancer
Yao L, Peng W, Li S, Shao Z. Shanghai Cancer Center, Shanghai, China.
P5-07-10 APOBEC3B drives mutagenesis in breast cancer
Harris RS. University of Minnesota, Masonic Cancer Center, Minneapolis, MN.
P5-07-11 Withdrawn
   
  Tumor Cell and Molecular Biology: Drug Resistance
P5-08-01 Systematic interrogation of resistance to HER2-directed therapy identifies a survival pathway activated by PRKACA and PIM1
Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo LY, Thomas SR, Boehm JS, Kim SY, Wang ZC, Hahn WC. Dana-Farber Cancer Institute, Boston, MA; Broad Institute, Cambridge, MA; Duke University, Durham, NC; Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
P5-08-02 New target in the resistant mechanism to trastuzumab
Vu TT, Zhang Q, Tian L, Shackleford T, Kute T, Claret FX. University of Texas M.D Anderson Cancer Center, Houston, TX; Wake Forest University School of Medicine, Winston-Salem, NC.
P5-08-03 In vitro resistance to ERBB2-targeted therapies does not bestow cross-resistance to antibody dependent cellular cytotoxicity
Olson RM, Ward TM, Jegg AM, Liu X, Pegram MD. Stanford University, Stanford, CA; University of Miami, Miami, FL.
P5-08-04 Overexpression of CXCR-4 confers trastuzumab resistance in human breast cancer cell lines
Mehta A, Wang-Kolodji GK, Tripathy D. University of Southern Californa, Los Angeles, CA.
P5-08-05 The influence of doxorubicin on PTEN and PI3K-Akt-mTOR signaling in human breast cancer
Austreid E, Knappskog S, Lønning PE, Eikesdal HP. University of Bergen, Bergen, Norway; Haukeland University Hospital, Bergen, Norway.
P5-08-06 PI3K blockade enhances the antitumor activity of eribulin in PIK3CA-mutant eribulin-resistant tumor xenografts
Serra V, Gris-Oliver A, Saura C, Oliveira M, Piris A, Ibrahim YH, Prudkin L, Pérez-García JM, Baselga J, Cortés J. Vall d'Hebron Institute of Oncology, Barcelona, Spain; MSKCC, New York, NY.
P5-08-07 HER3, MET and immune pathways play important roles in the resistance of triple negative breast cancer (TNBC) after neoadjuvant anti-EGFR (panitumumab) combined with FEC 100
Radosevic-Robin NZ, Abrial C, Dauplat MM, Kwiatkowski F, Cayre A, Maury F, Roche M, Chalabi N, Mouret-Reynier MA, Penault-Llorca F, Nabholtz JM. Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France.
P5-08-08 A human epidermal growth factor receptor 3 (HER3)-binding nanoparticle targets and kills Herceptin®-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Sims JD, Taguaim M, Hanson C, Cui X, Medina-Kauwe LK. Cedars-Sinai Medical Center, Los Angeles, CA; The University of California Los Angeles Geffen School of Medicine, Los Angeles, CA. Jessica D. Sims is a recipient of an AACR Scholar-In-Training Award
P5-08-09 Synergistic cytotoxicity of digoxin and 5-fluorouracil in doxorubicin-resistant breast cancer cell lines
Niu J, Zhang Y, Qiu Y, Clark S, Maddona MB, Chu F. Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, AZ; Lurie Children's Hospital, Chicago, IL; Northwestern University, Chicago, IL.
P5-08-10 Upregulation of microRNA-181a promotes metastasis of breast cancer cells following chemotherapy
Niu J, Shi Y, Wu Z-H. University of Tennessee Health Science Center, Memphis, TN; Center for Adult Cancer Research, University of Tennessee Health Science Center, Memphis, TN.
P5-08-11 Effects of miR-130a on chemosensitivity of human breast cancer cells to adriamycin by targeting PTEN
Tang J, Chen Z, Chen w, Zhong S, Zhao J. Jiangsu Cancer Hospital, the Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; Jiansu Cancer Hospital, the Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; Jiansu Cancer Hospital, the Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiansu, China.
P5-08-12 Histopathological and immunohistochemical findings for epithelial-to-mesenchymal transition were associated with clinical progressive disease of triple-negative breast cancers during neoadjuvant chemotherapy
Tanabe Y, Tsuda H, Yamamoto H, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y. National Cancer Center Hospital.
P5-08-13 Alteration of sensitivity to chemotherapeutic agents in tamoxifen resistant estrogen receptor positive breast cancer
Watanabe T, Okada T, Oba T, Iesato A, Hanamura T, Kanai T, Maeno K, Ito K-I. Shinshu University School of Medicine, Matsumoto, Japan.
P5-08-14 Deregulated histone and cell cycle pathways are associated with anthracycline resistance in breast cancer
Braunstein M, Liao L, Lyttle N, Taylor KJ, Krzyzanowski P, Kalatskaya I, Stein L, Marcellus R, Al-Awar R, Bartlett JMS, Spears M. Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada; Ontario Cancer Institute, Toronto Medical Discovery Tower, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Edinburgh Cancer Research Centre, Western General Hospital, Toronto, ON, Canada.
   
  Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
P5-09-01 Comprehensive gene assessment of estrogen receptor positive breast cancer reveals that HER2 plays an important role in resistance to neoadjuvant letrozole
Webber V, Turnbull AK, Larionov AA, Renshaw L, Sims AH, Dixon JM. Melville Trust Research Fellow, Western General Hospital, Edinburgh, United Kingdom; Breakthrough Research Unit, Western General Hospital, Edinburgh, United Kingdom. Victoria L. Webber is a recipient of an SABCS Clinical Scholars scholarship
P5-09-02 Cell culture models to study mechanisms for endocrine resistant breast cancer, new treatment options and new biomarkers
Lykkesfeldt AE, Yde CW, Thrane S, Larsen SL, Pedersen AM, Thomsen MBH, Kirkegaard T. Danish Cancer Society Research Center, Copenhagen, Denmark.
P5-09-03 Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance
Sikora MJ, Cooper KL, Bahreini A, Luthra S, Chandran UR, Wang G, Dabbs DJ, Welm AL, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Utah, Salt Lake City, UT.
P5-09-04 The effect of nuclear factor kappa B activation on cell proliferation of estrogen receptor positive breast cancer cell lines with different HER2-status
Sas L, Dirix L, Vermeulen P, Van Dam P, Lardon F, Van Laere S. Translational Cancer Research Unit, Oncology Centre, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Antwerp, Belgium; KU Leuven, Leuven, Belgium.
P5-09-05 Progranulin (GP88) expression and letrozole resistance in breast cancer
Serrero G, Dong J, Yue B, Tkaczuk KR, Chumsri S, Hayashi J. A&G Pharmaceutical Inc., Columbia, MD; Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD.
P5-09-06 Withdrawn
P5-09-07 Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies
Cottu PH, Bièche I, de la Grange P, Gentien D, Assayag F, Thuleau A, El-Botty R, Chateau-Joubert S, Huerre M, Hatem R, Richon S, Slimane K, Marangoni E. Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France.
P5-09-08 A comparison of the non-genomic effects of endoxifen and tamoxifen in aromatase inhibitor resistant breast cancer: Differential effects on the estrogen receptor co-regulator SRC3 (AIB1) and identification of PKC and PI3K as endoxifen substrates
Goetz MP, Kuffel M, Reinicke KE, Huang Z, Bode AM, Cheng J, Hoskin T, Suman VJ, Artega C, Reid J, Hawse J, Ames M. Mayo Clinic, Rochester, MN; Hormel Institute, University of Minnesota, Austin, MN; Vanderbilt University, Nashville, TN.
P5-09-09 ESRP1 and ESRP2 expression in tamoxifen resistance
Gökmen-Polar Y, Goswami CP, Gu X, Nakshatri H, Badve S. Indiana University School of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis.
P5-09-10 Androgen receptor signal acquired oncogenic role in aromatase inhibitor resistant model of breast cancer cell
Fujii R, Hanamura T, Niwa T, Yamaguchi Y, Ishida T, Sasano H, Ohuchi N, Hayashi S-I. Graduate School of Medicine, Tohoku University, Sendai, Japan; Graduate School of Medicine, Shinsyu University, Matsumoto, Japan; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
P5-09-11 BP1, a homeoprotein, regulates estrogen receptor alpha and induces estrogen independence
Berg P, Kirolikar S, Ginsburg E, Schwartz A, Simmens S. The George Washington University, Washington, DC; Mammary Biology and Tumorigenesis Laboratory, National Cancer Institute, National Institutes of Health; George Washington University Medical Center.
P5-09-12 Novel role of proto-oncogene PELP1 in A-NHEJ pathway of double strand break repair: Implications for treatment of hormonal therapy resistance
Krishnan SR, Nair BC, Mann M, Saareddy GR, Stark J, Gorbunova V, Vadlamudi RK. University of Texas Health Science Center at San Antonio, San Antonio, TX; University of Rochester; City of Hope.
P5-09-13 HDAC inhibition re-sensitizes acquired hormone resistant cells to the cytotoxic effect of tamoxifen
Raha P, Thomas S, Thurn KT, Chen S, Munster PN. University of California, San Francisco, CA.
P5-09-14 Plant-derived estrogen receptorβ agonists alone or in combination with aromatase inhibitors restore sensitivity in endocrine therapy resistant breast tumors
Samayoa C, Krishnegowda NK, Vadlamudi RK, Tekmal RR. University of Texas Health Science Center at San Antonio, San Antonio, TX.
P5-09-15 Polymorphism of the CYP2D6 gene in Brazilian women with breast cancer treated with tamoxifen
da Silva BB, de Vasconcelos-Valença RJ, Lopes-Costa PV, Gebrim LH. Federal University of Piauí (UFPI); Federal University of Sao Paulo (UNIFESP).
P5-09-16 Contribution of estrone-sulfate to cell proliferation in aromatase inhibitor resistance of estrogen receptor positive breast cancer
Higuchi T, Endo M, Gohno T, Hanamura T, Niwa T, Yamaguchi Y, Horiguchi J, Takeyoshi I, Hayashi S-I. Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan; Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan; Shinshu University School of Medicine, Matsumoto, Nagano, Japan; Research Institute for Clinical Oncology, Saitama Cancer Center, Ina, Kita-adachi-gun, Japan.
P5-09-17 Prognostic significance of progesterone receptor in hormonal receptor-positive breast cancer: Association with endocrine resistance
Bae SY, Lee SK, Lee JH, Lee H, Kim M, Kim J, Kil WH, Lee JE, Nam SJ. Samsung Medical Center, Seoul, Republic of Korea.
P5-09-18 Vitamin D3 supplementation, musculoskeletal (MS) symptoms and aromatase inhibitor (AI) pharmacokinetics from the vitamin D3AI study
Shapiro AC, Kirstein MN, Robien K, Swenson KK, Nissen MJ, Menk JS, Adlis S, Tsai M, Lerner R, Strayer L, Zwicky K. Frauenshuh Cancer Center and Park Nicollet Institute, St Louis Park, MN; University of Minnesota, Minneapolis, MN; Virginia Piper Cancer Institute Allina Health Services, Minneapolis, MN; George Washington University, Washington, DC.
P5-09-19 Progesterone receptor isoform A as a predictive marker of antiprogestin therapy in breast cancer: A tissue culture method to evaluate drug responsiveness
May M, Rojas P, Sequeira G, Martinez P, Gonzalez P, Gass H, Lanari C. IByME, Caba, Buenos Aires, Argentina; Hospital General de Pacheco, Buenos Aires, Argentina.
P5-09-20 Development of a novel selective estrogen receptor down-regulator which shows efficacy in pre-clinical models of endocrine resistance
Weir H, Nardone A, Lawson M, Rowlinson R, Hulse M, Powell S, Callis R, Walker G, Curwen J, Wilson Z, Bradbury R, Rabow Al, de Savi C, Pazolli E, Reavey N, D'Cruz C, Schiff R. AstraZeneca, Macclesfield, United Kingdom; AstraZeneca, Waltham, MA; Baylor College of Medicine, Houston, TX.
P5-09-21 Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Dalton JT, Narayanan R, Steiner MS. GTx, Inc.
   
  Tumor Cell and Molecular Biology: Systems Biology
P5-10-01 A systems approach to combine genomics and emerging therapeutics to discover new treatments for TNBC
Goga A, Martins M, Corella A, Horiuchi D, Samson S, Bandyophadyay S. University of California, San Francisco.
P5-10-02 Investigating the response and adaptation of estrogen receptor (ER)+ tumors in response to decreased estrogen availability using an agent-based model of the mammary epithelium
Chapa JA, Kulkarni SA, An G. University of Chicago Pritzker School of Medicine, Chicago, IL; University of Chicago, Chicago, IL.
P5-10-03 Estrogen, obesity and mammary morphology in a middle-aged rat model of menopause
Liang J, Davis JD, Garcia AN, Wolfe A, Gore AC, Yin W. College of Natural Science, University of Texas at Austin; College of Pharmacy, The University of Texas at Austin; The University of Texas at Austin; Institute for Neuroscience, The University of Texas at Austin, Austin, TX; Johns Hopkins University School of Medicine, Baltimore, MD.
   
  Tumor Cell and Molecular Biology: Tumor Biology – Other
P5-11-01 Impact of CDK mediated Smad3 phosphorylation and Pin1 in triple negative breast cancer cell migration
Hamdan R, Jeruss JS. Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.
P5-11-02 Radiation instigates EMT, CSC self renewal and pluripotency signal transduction in non-targeted (bystander) ERα+ and triple-negative breast cancer cells
Khan FH, Natarajan M, Aravindan S, Herman TS, Aravindan N. University of Oklahoma Health Sciences Center, OKlahoma City, OK; University of Texas Health Science Center, San Antonio, TX; Stephenson Cancer Center, Oklahoma City, OK.
P5-11-03 Deciphering the role of HER3-DJ-1 interaction in breast cancer
Mukherjee S, Huang Z, Fa M, Dhupkar P, Mujoo K, Zhang N, An Z. UT Houston M.D Anderson Cancer Center, Houston, TX.
P5-11-04 Post-translational modification of the cell-fate factor Dachshund determines p53 binding and signaling modules in breast cancer
Pestell RG, Chen K, Wu K, Gormley M, Ertel A, Zhang W, Zhou J, DiSante G, Li Z, Rui H, Quong AA, McMahon SB, Deng H, Lisanti MP, Wang C. Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY.
P5-11-05 Overexpression of girdin in nucleus indicates poor disease-free survival in ER-positive breast cancer
Peng W-T, Hu X, Yao L, Jiang Y-Z, Yu K-D, Shao Z-M. Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China. Wenting Peng is a recipient of an Avon-AACR International Scholar-In-Training Award
P5-11-06 Combination of insulin-like growth factor 1 receptor and PI3K/mTOR inhibition in triple-negative breast cancers
Liu T, Taliaferro-Smith LD, O'Regan R. Winship Cancer Institute of Emory University, Atlanta, GA.
P5-11-07 Role of Wnt/β-catenin signaling on radiation resistance in basal-like breast cancer
Smith DL, Debeb BG, Larson RA, Woodward WA. MD Anderson Cancer Center, Houston, TX.
P5-11-08 SRA/SRAP contributes to TGF-β1 induced cell motility in cancer cells
Cooper CM, Yan Y, Xu W, Tsuyuki D, Hamedani MK, Davie JR, Leygue E. Manitoba Institute of Cell Biology, Cancercare Manitoba, Winnipeg, MB, Canada; Biochemistry and Medical Genetics University of Manitoba, Winnipeg, MB, Canada; Manitoba Institute of Child Health, Winnipeg, MB, Canada.
P5-11-09 Crk II adaptor proteins as positive regulators of HER3 signaling in breast cancer
Dhupkar P, Zhao H, Mukherjee S, Mujoo K, Zhang N, An Z. University of Texas M.D. Anderson Cancer Centre, Houston, TX.
P5-11-10 Effect of claudin-3 protein expression on its sub-cellular localization and cellular motility in breast cancer cell lines
Petty HM, King JM, Cuevas ME, Sheller RA, Todd MC. Southwestern University, Georgetown, TX; Trinity University, San Antonio, TX.
   
  Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects
P5-12-01 A comparison of hormone receptor status in black women born in the U.S., West Africa, East Africa and the Caribbean - A SEER analysis
Haynes BM, Ruterbusch JJ, Simon MA, Cote ML. Wayne State University, Detroit, MI.
P5-12-02 Estrogen receptor, progesterone receptor and HER2 expression in breast cancer: Do Indians differ from their American counterpart? A study from South India
Rao N, Basavalinga AS, Prabhudesai S, Hazarika D, Gangoli A, Krishnamoorthy N. Bangalore Institute of OncologySpeciality Centre, Bangalore, Karnataka, India; Triesta Sciences, Bangalore, Karnataka, India.
P5-12-03 Racial differences in breast cancer survival in a large urban integrated health system
Simon MS, Ruterbusch JJ, Pressler ME, Lamerato L, Krajenta R, Booza JC, Schwartz K. Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI.
P5-12-04 Ethnicity disparities of breast cancer in an insured population
Zhu X, Decker V, Almodovar AJO, Litherland SA, Decker DA. Florida Hospital Cancer Institute, Orlando, FL.
P5-12-05 Racial and gender disparity in breast cancer: A review on African American men
Miles KC, Onyewu SC, Obirieze A, Frederick WAI, Dewitty R, Leffall LD, Horton S, Wilson L. Howard University Hospital, Washington, DC.
P5-12-06 Benchmarking biopsy pathology resolution for breast disease
Kirkness CS, Ren J, Doubet DK, Mammolito DM, Jalovec LM, Ramakrishna RS, Kennell KA, Guingrich JA. University of Illinois College of Medicine at Peoria, Peoria, IL; OSF Healthcare, Peoria, IL.
P5-12-07 Triple-negative breast cancer in African American women - How women in New Orleans compare to the rest of Louisiana and the Nation
Loch M, Li X, Estrada J, Reske T, Chen V, Wu X-C. Louisiana State University Health Sciences Center, New Orleans, LA.
P5-12-08 Survival differences by stage and race/ethnicity using the Nottingham prognostic index
Parise C, Caggiano V. Sutter Institute for Medical Research, Sacramento, CA.
P5-12-09 Clinical stage, not race, predicts receipt of sentinel lymph node biopsy in medically-underserved patients
Wiatrek RL, Kao LS, Robinson EK, Rieber AG, Ko TC, Wray CJ. University of Texas Medical School at Houston, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX.
P5-12-10 Pathological characteristics and patterns of recurrence and mortality among young Mexican breast cancer patients
Villarreal-Garza CM, Hoyos CM, Meza-Herrera V, Palacios VA, Hernandez-Vega MB, Aguila C, Lara-Medina F, Meneses A, Mohar A. Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima.
P5-12-11 Evaluating overweight/obesity and physical activity rates in an ethnically diverse sample of breast cancer survivors
Cunningham JE, Bauza CE, Brown ET, Alberg AJ, Kistner-Griffin E, Spruill IJ, Bryant DC, Charles KD, Esnaola NF, Jefferson MS, Whitfield KE, Kramer RM, Bolick S, Hurley D, Mosley C, Hazelton TR, Bea VJ, Burshell DR, Ford ME. Medical University of South Carolina (MUSC), Charleston, SC; MUSC Hollings Cancer Center, Charleston, SC; Morehouse School of Medicine, Atlanta, GA; Temple University School of Medicine, Philadelphia, PA; Duke University, Durham, NC; South Carolina Department of Health and Environmental Control, South Carolina Central Cancer Registry, Columbia, SC.
   
  Epidemiology, Risk, and Prevention: Epidemiology, Risk, and Prevention - Other
P5-13-01 Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ
Sivasubramanian PS, Reimers LL, Greenlee H, Terry MB, Hershman D, Maurer M, Kalinsky K, Awad D, Xiao T, Sandoval R, Alvarez M, Quirarte A, Campbell J, Crew KD. Columbia University, New York, NY.
P5-13-02 Withdrawn
P5-13-03 Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer
Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woodson A, Jessica P, Kuerer H, Litton J, Arun B. University of Texas M.D.Anderson Cancer Center, Houston, TX.
P5-13-04 What's your excuse?: Reasons women with a first degree family history of breast cancer don't get mammograms
Hibler L, Hofstatter EW, Chagpar AB. Yale University School of Medicine, New Haven, CT.
P5-13-05 Richer and wiser: Factors correlated with chemoprevention use in the United States
Hofstatter EW, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A. Yale University School of Medicine, New Haven, CT.
P5-13-06 Seasonal variation in onset of inflammatory breast cancer: Evidence of an infectious trigger
Hashmi S, Liu Y, Bethony J, Cristofanilli M, Levine PH. The School of Medicine and Health Sciences, The George Washington University, Washington, DC; The George Washington University School of Public Health and Health Sciences, Washington, DC; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
P5-13-07 Genetic polymorphism of estrogen metabolizing enzyme CYP17A1 rs743572 impacts on serum testosterone level in Japanese premenopausal women
Yoshimoto N, Nishiyama T, Yamashita H, Takahashi S, Shiraki N, Sugiura H, Endo Y, Iwasa M, Asano T, Hato Y, Fujii Y, Toyama T. Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan; Nagoya City West Medical Center, Nagoya, Aichi, Japan.
P5-13-08 Withdrawn
P5-13-09 Evaluation on the risk factors and prognosis for patients with synchronous bilateral breast cancer in a Chinese cohort
Chen J-J, Wang Y, Xue J-Y, Yang B-L, Huang S, Chen Y, Chen J-Y, Yang W-T, Shao Z-M, Wu J. Shanghai Cancer Center, Fudan University, Shanghai Medical College, Fudan University, Shanghai, China.
P5-13-10 Quality of care for premenopausal patients with early-onset breast cancer in Germany
Fischer D, Hedderich M, Heinrich A, Wedel B, Banz-Jansen C, Rody A, Waldmann A. University of Schleswig-Hlstein, Campus Luebeck, Luebeck, Germany; University of Hamburg Eppendorf, Hamburg, Germany; Institute of Epidemiology and Social Medicine, University of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
P5-13-11 Characteristics of women under age 40 years served by organizations funded to conduct education and outreach to link medically underserved women with breast cancer screening services through the Avon breast health outreach program
Hallum-Montes RM, Opdyke KM, Aliaga M, Hurlbert M, Gates-Ferris K. CAI Global, New York, NY; Avon Foundation for Women, New York, NY.
P5-13-12 Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/ hepatitis B core antibody positive and/or hepatitis B surface antibody positive breast cancer patients who receive chemotherapy
Hattori M, Ito Y, Takahashi S, Fukada I, Iwase T, Iwata H, Hatake K. Aichi Cancer Center, Nagoya, Japan; Cancer Institute Hospital of JFCR, Tokyo, Japan.
P5-13-13 Comorbidity and survival of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents
Landsman-Blumberg P, Hao Y, Meyer N, Johnson W, Willemann Rogerio J. Truven Health Analytics, Cambridge, MA; Novartis Pharmaceuticals, East Hanover, NJ; Truven Health Analytics, Washington, DC.
P5-13-14 Breast cancer in very young patient is a more aggressive entity independent from breast cancer subtype
Martínez MT, Peña-Chilet M, Perez-Fidalgo JA, Bosch A, Alonso E, Ferrer J, Burgues O, Bermejo B, Lluch A, Ribas G. Health Research Institute INCLIVA, Valencia, Spain; Dr. Baselga Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY.
P5-13-15 Process-of-care: Elucidating delays in surgical treatment of breast cancer
Golshan M, Weingart SN, Losk K, Hirshfield-Bartek J, Cutone L, Abeita J, Kadish S, Bunnell C. Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.
   
  Treatment: Radiation Therapy
P5-14-01 Chest wall bolus in post-mastectomy radiotherapy – Is it really necessary?
Yap ML, Sappiatzer J, Tieu MT, Cuartero JF, Panzarella T, McCready D, Fyles A. Princess Margaret Cancer Centre, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.
P5-14-02 Postmastectomy radiation improves loco-regional control for patients with advanced breast cancer treated with neoadjuvant chemotherapy
Fujita T, Sawaki M, Hattori M, Naoto K, Horio A, Gongou N, Ichikawa M, Idota A, Adachi Y, Hisada T, Kotani H, Ishiguro J, Iwata H. Aichi Cancer Center Hospital, Nagoya, Japan.
P5-14-03 The impact of adjuvant radiotherapy on survival in primary breast cancer: What is the role of guideline adherence in radiotherapy – A retrospective multi-center cohort study of 8935
Wöckel A, Wolters R, Wiegel T, Janni W, Kreienberg R, Wischnewsky M, Schwentner L. University Ulm, Ulm, Germany; University Bremen, Bremen, Germany.
P5-14-04 Preoperative single-fraction partial breast radiotherapy – Initial results from a novel phase I dose-escalation protocol with exploration of radiation response biomarkers
Horton JK, Blitzblau RC, Yoo S, Georgiade GS, Geradts J, Baker JA, Chang Z, Broadwater G, Barry W, Duffy EA, Hwang ES. Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA.
P5-14-05 Preoperative accelerated partial breast irradiation (PAPBI) trial: First results on acute toxicity, complications and cosmetic results
van der Leij F, Bartelink H, Rutgers E, Rivera S, van den Bongard D, Lekberg T, Elkhuizen P. Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institut Goustave Roussy, Villejuif, France; University Medical Center Utrecht, Utrecht, Netherlands; Karolinska Instutet, Stockholm, Sweden.
P5-14-06 Outcomes in 500 patients from a large, retrospective study of APBI with a strut-based breast brachytherapy applicator
Yashar C, Butler E, Einck JP, Finkelstein SE, Graves YJ, Han B, Hong RL, Komarnicky LT, Lyden M, Mahalingam SB, Mantz CA, Nasr N, Nigh SS, Pollock J, Reiff JE, Scanderbeg D, Snyder MR, Strasser JF, Kuske RR. University of California San Diego, La Jolla, CA; Schiffler Cancer Center, Wheeling, WV; 21st Century Oncology Translational Research Center (TRC), Scottsdale, AZ; South Florida Radiation Oncology, Boynton Beach, FL; Virginia Hospital Center, Arlington, VA; Drexel University College of Medicine, Philadelphia, PA; BioStat International, Inc., Tampa, FL; The Christ Hospital Cancer Center, Cincinnati, OH; 21st Century Oncology, Fort Myers, FL; Northwest Community Hospital, Arlington Heights, IL; Christiana Care Health System, Newark, DE; Arizona Breast Cancer Specialists, Phoenix, AZ.
P5-14-07 Comparison of infectious complications between breast conserving therapy with catheter-based accelerated partial irradiation and whole breast irradiation
Shen MC, Bloom E, Shaitelman SF, Wei C, Haynes AB, Abdel-Rahman S, Mittendorf EA, Kuerer HM, Bedrosian I, Hwang R, Hunt K, Tereffe W, Strom E, Babiera GV. MD Anderson Cancer Center, Houston, TX.
P5-14-08 Prospective phase II study of concurrent capecitabine and radiation demonstrates futility in triple negative chemo-resistant breast cancer
Woodward WA, Arriaga L, Gao H, Cohen EN, Li L, Reuben JM, Munsell MF, Valero V, Le-Petross H, Melhem-Betrandt A, Moulder S, Middleton LP, Strom EA, Tereffe W, Hoffman K, Smith BD, Buchholz TA, Perkins GH. The University of Texas MD Anderson Cancer Center, Houston, TX.
P5-14-09 Brachytherapy, 3-dimentional conformal radiotherapy, and intensity modulated radiotherapy for breast cancer patients undergoing breast conservation: Effectiveness and guideline concordance
Huo D, Czechura T, Winchester DJ, Winchester DP, Yao K. University of Chicago, Chicago, IL; NorthShore University HealthSystem, Evanston, IL.
P5-14-10 Adjuvant intra-operative electron-beam therapy for early invasive breast carcinoma using non-dedicated linear accelerator: Toxicity, efficacy, and aesthetic satisfaction
Hanna SA, Carvalho HA, Andrade FEM, Bevilacqua JLB, Piato JRM, Docema MFL, Barros ASCD. Hospital SirioLibanês, Sao Paulo, SP, Brazil.
P5-14-11 Locoregional toxicities after adjuvant radiotherapy with or without concurrent bevacizumab in patients with non-metastatic breast cancer
Pernin V-E, Belin L, Gobillion A, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Bougnoux P, Peignaux K, Denis F, Kirova Y. Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France.
P5-14-12 Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: An objective assessment of patients from a randomized controlled trial
Keshtgar M, Williams NR, Corica T, Bulsara M, Saunders C, Flyger H, Bentzon N, Cardoso JS, Michalopoulos N, Joseph DJ. Royal Free Hospital, London, United Kingdom; UCL, London, United Kingdom; Sir Charles Gairdner Hospital, Perth, Australia; University of Notre Dame, Fremantle, Australia; Herlev Hospital, Copenhagen, Denmark; University of Porto, Porto, Portugal.
P5-14-13 An observational study using γ-H2AX foci to investigate cardiac doses of radiation in women following adjuvant radiotherapy for breast cancer: External beam radiotherapy versus targeted intraoperative radiotherapy
Woolf DK, Williams NR, Bakhshi R, Madani Y, Fawcitt S, Pigott K, Short SC, Keshtgar M. Royal Free Hospital NHS Trust, London, United Kingdom; UCL, London, United Kingdom; Leeds Institute of Cancer and Pathology, Leeds, United Kingdom.
P5-14-14 Trimodality therapy for inflammatory breast cancer: The Fox Chase experience
Townsend NC, Klayton TL, Tianyu L, Anderson PR, Hayes S. Fox Chase Cancer Center, Philadelphia, PA; West Penn Allegheny Cancer Institute, Pittsburgh, PA.
P5-14-15 Discovery and validation of simple heart measurements to screen patients who will benefit from deep inspiration breath hold for left breast irradiation
Carlson R, Hiemstra K, Pearson S, Qiu X, Xu W, Fyles A, Chung C. Princess Margaret Cancer Centre, Toronto, ON, Canada.
P5-14-16 Hypofractionated breast irradiation in early-stage breast cancer patients following adjuvant chemotherapy: Evaluation of acute and late toxicities
Young R, Kabarriti R, Hannan R, Hong L, Kalnicki S, Fox JL. Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY; UT Southwestern, Dallas, TX.
P5-14-17 Post-lumpectomy tumorbed delineation for breast boost or partial breast irradiation: The influence of additional MRI and CT imaging
den Hartogh MD, Philippens MEP, van Dam IE, Kleynen CE, Tersteeg RJHA, Kotte ANTJ, van Vulpen M, van Asselen B, van den Bongard DHJG. University Medical Center Utrecht, Utrecht, Netherlands.
P5-14-18 Indication of post-mastectomy radiation associated with risk of local recurrence in breast cancer patients with 1-3 lymph node metastasis
Saruwatari A, Ishida M, Koi Y, Akiyoshi S, Igawa A, Oikawa M, Koga C, Nishimura S, Nakamura Y, Ohno S. Natinal Kyushu Cancer Center, Fukuoka, Japan
P5-14-19 Radiation field design on the ACOSOG Z0011 trial
Jagsi R, Ballman K, Chadha M, Moni J, Laurie F, Buchholz TA, Haffty BG, Giuliano A. University of Michigan, Ann Arbor, MI; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Beth Israel Medical Center, New York, NY; University of Massachusetts Medical School, Worcester, MA; Quality Assurance Review Center (QARC), Lincoln, RI; MD Anderson Cancer Center, Houston, TX; Rutgers-Cancer Institute of New Jersey, New Brunswick, NJ; John Wayne Cancer Center, Santa Monica, CA.
   
  Treatment: Breast Conservation
P5-15-01 Comparative effectiveness of four treatment modalities for early stage breast cancer patients
Schroeder MC, Tien Y-Y, Thomas A, Keating NL, Brooks JM. University of Iowa, Iowa City, IA; Harvard Medical School, Boston, MA.
P5-15-02 Beyond the learning curve: Surgical judgment in the approach to breast conserving surgery
Schnabel F, Billig J, Schwartz S, Chun J, Breast Surgery Service at the NYU Langone Medical Center. NYU Cancer Institute, NYU Langone Medical Center, New York, NY.
P5-15-03 Prediction of positive resection margins in patients with non-palpable breast cancer
Barentsz MW, Postma EL, van Dalen T, van den Bosch M, Hui M, Gobardhan PD, Witkamp AJ, van Diest PJ, van Gorp J, van Hillegersberg R, Verkooijen HM. University Medical Center Utrecht, Utrecht, Netherlands; Diakonessenhuis Utrecht, Utrecht, Netherlands; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore; Amphia Hospital Breda, Breda, Netherlands.
P5-15-04 Clinical benefits of using nomogram for predicting positive resection margins in breast conserving surgery
Lee E, Han W, Moon H-G, Kim J, Lee JW, Kim MK, Yoo T-K, Kim J, Noh D-Y. Seoul National University College of Medicine, Seoul, Republic of Korea.
P5-15-05 The impact of a change in margin width policy on rates of re-operation for breast conserving surgery
Richardson CE, Arima Y, Wishart GC, Ambler GK, Benson JR. Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, United Kingdom; Anglia Ruskin University, Cambridge, United Kingdom.
P5-15-06 Surgical management of breast cancer in BRCA-mutation carriers: A clinical approach based on a systematic review
Valachis A, Nearchou AD. Mälarsjukhuset, Eskilstuna, Sweden; University of Uppsala, Uppsala, Sweden.
P5-15-07 Therapeutic mammaplasty - Radical breast conservation or conservative mastectomy? A comperative analysis of 1000 patients' pathology results
Mansell J, Martin J, Khan A, Weiler-Mithoff E, Stallard S, Doughty JC, Romics L. Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow.
P5-15-08 Clinical factors that contribute to choice of mastectomy in patients eligible for breast conservation therapy
Reese AS, Kesmodel SB, Bellavance EC, Reese JB, Campassi C, Tkaczuk KH, Bao T, Chumsri SS, Olson JA, Feigenberg SJ. University of Maryland Medical Center, Baltimore, MD; The Johns Hopkins University School of Medicine, Baltimore, MD.
P5-15-09 A new method for marking the lumpectomy cavity during oncoplastic surgery and breast conservation
Glaser CC, Cross MJ, Harman J. Owensboro Regional Medical Center, Owensboro, KY; Breast Treatment Associates, Fayetteville, AR; St Mark's Breast Centre, Auckland, New Zealand.
   
  Treatment: DCIS/LCIS
P5-16-01 Withdrawn
P5-16-02 Risk of subsequent ipsilateral invasive breast cancer after a primary diagnosis of ductal carcinoma in situ
Elshof LE, Schaapveld M, Schmidt MK, Boekel NB, van Leeuwen FE, Wesseling J. Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, Netherlands.
P5-16-03 Influence of radiotherapy boost in patients with ductal carcinoma in situ of breast cancer: A multicenter, retrospective study in Korea (KROG 11-04)
Kim JH, Choi DH, Park W, Ha SW, Kim K, Ye JW, Suh C-O, Shin KH, Kim DW, Lee JH. Dongsan Medical Center Keimyung University School of Medicine; Samsung Medical Center Sungkyunkwan University School of Medicine; Seoul National University Hospital; Yeungnam University Medical Center; Severance Hospital Yonsei University College of Medicine; National Cancer Center; Pusan National University Hospital; Ewha Womans University Mokdong Hospital.
P5-16-04 Predictive biomarkers for invasion on final pathology in patients with preoperative diagnosis of ductal carcinoma in situ of the breast by needle biopsy
Mori M, Krings G, Chan L, Chen Y-Y, Kerlikowske K, Tlsty TD, Matsuda N, Suzuki K, van 't Veer L. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; University of California, San Francisco, San Francisco, CA; St. Luke's International Hospital, Chuoku, Tokyo, Japan.
P5-16-05 Comparative analysis of the immunohistochemical profile of ductal carcinoma in situ to invasive ductal carcinoma
Orozco JIJ, Gago FE, Ciocca DR, Mendiondo BS, Ciocca LA, Ibarra MJ, Tello OM. Italian Hospital of Mendoza, Guaymallen, Mendoza, Argentina; Gynecologic Area. School of Medical Sciences, National University of Cuyo, Capital, Mendoza, Argentina; Institute of Experimental Medicine and Biology of Cuyo, Scientific and Technological Center, CONICET, Capital, Mendoza, Argentina; School of Odontology, National University of Cuyo, Capital, Mendoza, Argentina.
P5-16-06 Withdrawn
P5-16-07 Intracystic papillary carcinoma of the breast: Implications for therapy from the surveillance epidimiology and end results database
Howard-McNatt M, Brown D, Levine E, Isom S. Wake Forest Baptist Medical Center, Winston-Salem, NC.
   
  Treatment: Treatment - Other
P5-17-01 A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis
Cortazar P, Zhang L, Untch M, Mehta K, Constantino J, Wolmark N, Bonnefoi H, Piccart M, Gianni L, Valagussa P, Zujewski JA, Justice R, Loibl S, Swain SM, Bogaerts J, Baselga J, Prowell TM, Rastogi P, Sridhara R, Tang S, Pazdur R, Mamounas E, vonMincwitz G. FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany, D-13125; GBG Forschungs GmbH, Germany; NSABP, Pittsburgh, PA; Institut Bergonié, INSERM U916; Jules Bordet Institute, Brussels, Belgium; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; Medstar Washington Hospital Center, Washington, DC; EORTC Headquarters, Brussels, Belgium; Memorial Sloan-Kettering Cancer Center, New York; Orlando Health MD Anderson Cancer Center.
P5-17-02 Efficiency of methylene blue nanoparticles (nanoMB) as local injectable agent for photodynamic therapy in breast cancer
Park H, Kang JG, Choi HH, Kim WW, Hwang SO, Jung JH, Lee YH, Kim S. School of Medicine, Kyungpook National University, Daegu, Korea; Hyosung Medical Center, Daegu, Korea; Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea.
P5-17-03 A new strategy for testing therapies to be effective against seemingly untreatable cancers
Singh B, Raythatha MR, Shamsnia A, Lucci A. UT MD Anderson Cancer Center, Houston, TX.
   
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy